Christine A Hughes

Summary

Affiliation: University of Alberta
Country: Canada

Publications

  1. doi request reprint Abacavir hypersensitivity reaction: an update
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, HIV, Northern Alberta HIV Program and Regional Pharmacy Services, Capital Health Region, Edmonton, Alberta, Canada
    Ann Pharmacother 42:387-96. 2008
  2. doi request reprint Iatrogenic Cushing syndrome after intra-articular triamcinolone in a patient receiving ritonavir-boosted darunavir
    Jill J Hall
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
    Int J STD AIDS 24:748-52. 2013
  3. doi request reprint Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir
    Cara Hills-Nieminen
    Northern Alberta HIV Program and Regional Pharmacy Services, Alberta Health Services, Edmonton, AB, Canada
    Ann Pharmacother 43:2117-20. 2009
  4. doi request reprint New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Northern Alberta HIV Program, Edmonton, AB T6G 2N8, Canada
    Expert Opin Pharmacother 10:2445-66. 2009
  5. doi request reprint Interactions between antifungal and antiretroviral agents
    Christine A Hughes
    University of Alberta, Faculty of Pharmacy and Pharmaceutical Sciences, 3126 Dent Pharm Centre, Edmonton, AB, T6G 2N8 Canada
    Expert Opin Drug Saf 9:723-42. 2010
  6. ncbi request reprint Evaluation of a professional development course for pharmacists on laboratory values: can practice change?
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
    Int J Pharm Pract 18:174-9. 2010
  7. pmc Prenatal screening and perinatal HIV transmission in Northern Alberta, 1999-2006
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, 3126 Dentistry Pharmacy Centre, University of Alberta Edmonton, AB Canada T6G 2N8
    Am J Public Health 99:S412-6. 2009
  8. pmc Interaction between lopinavir/ritonavir and warfarin
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alta
    CMAJ 177:357-9. 2007
  9. ncbi request reprint Treatment of hepatitis C in HIV-coinfected patients
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, HIV, Capital Health Region, Edmonton, Alberta, Canada
    Ann Pharmacother 40:479-89; quiz 582-3. 2006
  10. ncbi request reprint Chronic hepatitis C virus management: 2000-2005 update
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
    Ann Pharmacother 40:74-82. 2006

Collaborators

Detail Information

Publications17

  1. doi request reprint Abacavir hypersensitivity reaction: an update
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, HIV, Northern Alberta HIV Program and Regional Pharmacy Services, Capital Health Region, Edmonton, Alberta, Canada
    Ann Pharmacother 42:387-96. 2008
    ..To review the clinical features, risk factors, diagnosis, and management of abacavir hypersensitivity reaction (HSR)...
  2. doi request reprint Iatrogenic Cushing syndrome after intra-articular triamcinolone in a patient receiving ritonavir-boosted darunavir
    Jill J Hall
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
    Int J STD AIDS 24:748-52. 2013
    ..We review the probable mechanism for this interaction and describe similar cases of Cushing syndrome in patients receiving concomitant ritonavir and triamcinolone. ..
  3. doi request reprint Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir
    Cara Hills-Nieminen
    Northern Alberta HIV Program and Regional Pharmacy Services, Alberta Health Services, Edmonton, AB, Canada
    Ann Pharmacother 43:2117-20. 2009
    ..To report the results of therapeutic drug monitoring of lopinavir/ritonavir and itraconazole concentrations in an HIV-infected male who was treated for histoplasmosis...
  4. doi request reprint New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Northern Alberta HIV Program, Edmonton, AB T6G 2N8, Canada
    Expert Opin Pharmacother 10:2445-66. 2009
    ..To derive maximum durability from the use of these newer drugs, a thorough understanding of their indications and limitations is critical...
  5. doi request reprint Interactions between antifungal and antiretroviral agents
    Christine A Hughes
    University of Alberta, Faculty of Pharmacy and Pharmaceutical Sciences, 3126 Dent Pharm Centre, Edmonton, AB, T6G 2N8 Canada
    Expert Opin Drug Saf 9:723-42. 2010
    ..With the availability of several new antiretroviral and antifungal agents, drug-drug interactions emerge as a potential safety concern...
  6. ncbi request reprint Evaluation of a professional development course for pharmacists on laboratory values: can practice change?
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
    Int J Pharm Pract 18:174-9. 2010
    ..The purpose of this study was to evaluate pharmacists' experience with a continuing professional development (CPD) course and its impact on pharmacists' knowledge, confidence and change in practice...
  7. pmc Prenatal screening and perinatal HIV transmission in Northern Alberta, 1999-2006
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, 3126 Dentistry Pharmacy Centre, University of Alberta Edmonton, AB Canada T6G 2N8
    Am J Public Health 99:S412-6. 2009
    ..We evaluated the effectiveness of a program that includes routine opt-out prenatal HIV screening, combination antiretroviral therapy (ART), and a multidisciplinary team in preventing perinatal HIV transmission...
  8. pmc Interaction between lopinavir/ritonavir and warfarin
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alta
    CMAJ 177:357-9. 2007
    ..We review the possible mechanisms of this interaction and the reported interactions between warfarin and other protease inhibitors...
  9. ncbi request reprint Treatment of hepatitis C in HIV-coinfected patients
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, HIV, Capital Health Region, Edmonton, Alberta, Canada
    Ann Pharmacother 40:479-89; quiz 582-3. 2006
    ..To review the current management of hepatitis C virus (HCV) in persons coinfected with HIV...
  10. ncbi request reprint Chronic hepatitis C virus management: 2000-2005 update
    Christine A Hughes
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
    Ann Pharmacother 40:74-82. 2006
    ..To review recent advances that have significantly changed the management of chronic hepatitis C virus (HCV) infection...
  11. doi request reprint Adverse effects of antiretrovirals in HIV-infected pregnant women
    Dalyce M Zuk
    Regional Pharmacy Services, Capital Health, Edmonton, Alberta, Canada
    Ann Pharmacother 43:1028-35. 2009
    ..It is unclear whether the risk of ARV-related adverse drug reactions (ADRs) is increased during pregnancy...
  12. doi request reprint Protease inhibitor-associated QT interval prolongation
    Kimberley Hunt
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
    Ann Pharmacother 45:1544-50. 2011
    ..To evaluate the literature on protease inhibitor (PI)-associated QT interval prolongation and risk for torsade de pointes in patients infected by HIV...
  13. doi request reprint Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3
    Vaninder K Sidhu
    Alberta Health Services, Edmonton, Alberta, Canada
    Ann Pharmacother 49:1343-8. 2015
    ..To review the evidence for discontinuing primary and secondary Pneumocystis jirovecii pneumonia (PJP) prophylaxis in HIV-infected patients with a CD4 count <200 cells/mm(3)...
  14. doi request reprint Induction effects of ritonavir: implications for drug interactions
    Michelle M Foisy
    Northern Alberta HIV Program and Regional Pharmacy Services, Capital Health Authority, Edmonton, Alberta, Canada
    Ann Pharmacother 42:1048-59. 2008
    ..To review the literature on the induction effects of ritonavir on the cytochrome P450 enzyme system and glucuronyl transferase and identify resultant established and potential drug interactions...
  15. doi request reprint Complexity of interactions between voriconazole and antiretroviral agents
    Erin M Yakiwchuk
    Regional Pharmacy Services, Capital Health Authority, Edmonton, Alberta, Canada
    Ann Pharmacother 42:698-703. 2008
    ..To evaluate and summarize pertinent aspects of the literature on interactions between voriconazole and antiretroviral agents...
  16. doi request reprint Comment: Abacavir hypersensitivity reaction: an update
    Christine A Hughes
    Ann Pharmacother 42:1519-20; author reply 1520-1. 2008
  17. ncbi request reprint Evaluation of HIV drug interaction web sites
    Nancy L Sheehan
    Immunodeficiency Service, McGill University Health Centre Montréal Chest Institute, Montreal, Quebec, Canada
    Ann Pharmacother 37:1577-86. 2003
    ..Clinicians frequently consult HIV drug interaction Web sites of unknown quality...